Incorporation of Vpx into human immunodeficiency virus type 2 (HIV-2) virus-like particles is mediated by the Gag polyprotein. We have identified residues 15 to 40 of Gag p6 and residues 73 to 89 of Vpx as being necessary for virion incorporation. In addition, we show enhanced in vitro binding of Vpx to a chimeric HIV-1/HIV-2 Gag construct containing residues 2 to 49 of HIV-2 p6 and demonstrate that the presence of residues 73 to 89 of Vpx allows for in vitro binding to HIV-2 Gag.
The genomes of lentiviruses encode several accessory proteins in addition to the essential Gag, Pol, and Env proteins. Vpx is an accessory protein which is found in human immunodeficiency virus type 2 (HIV-2) and in the simian immunodeficiency viruses (SIVs) SIV smm , SIV mnd , and SIV mac but is absent from HIV-1 (1, 6) . It has been speculated that the vpx gene is a result of the duplication of the vpr gene, which encodes another regulatory protein found in all lentiviruses (24) , or arose through the acquisition of the vpr gene from SIV AGM (21) . The proteins are similar in size (14 to 16 kDa), demonstrate amino acid sequence similarity, and are packaged within the virion. Vpx of HIV-2 and SIV is required for efficient viral replication in primary lymphocyte and monocyte cultures (5, 9, 16 ). It appears to be the primary determinant in these viruses for transport of the viral preintegration complex into the nuclei of quiescent cells (3) .
Vpx is packaged within the virion in molar amounts equivalent to those of the Gag proteins (4, 7), although it is dispensable for the assembly process (9) . This stoichiometry suggests that specific interactions with Gag could mediate the packaging of Vpx. In addition, HIV-2 Vpx appears to colocalize with HIV-2 Gag at the inner surface of the plasma membrane of infected cells (10) . Several conserved regions within Vpx could be involved in such an interaction with Gag, including (i) a predicted amphipathic helix between residues 20 and 40, (ii) three conserved cysteines at residues 73, 87, and 89, and (iii) a stretch of seven prolines at the C-terminal end of the protein (Fig. 1A ). Park and Sodroski studied the amino acid requirements for the packaging of SIV Vpx and determined that residues 78 to 80 and 82 to 87 are important (18) . Since the conserved cysteines are within or flanking this region, Park and Sodroski suggested that intramolecular disulfide bonds may be important for packaging due to their effects on the conformation of Vpx. In contrast, the domain of Vpr that is critical for virion incorporation has been mapped to the ␣-helical region (2) .
In addition to Vpx, the region within Gag required for Vpx packaging has been examined. It has previously been shown that residues 439 to 497 of HIV-2 Gag are required for the packaging of Vpx (25) . This region consists of the seven Cterminal residues of p1 and the 51 N-terminal residues of p6 (Fig. 2) . Similarly, the p6 protein is necessary and sufficient for the incorporation of Vpr into virions, and the region required has been mapped to residues 35 to 47 of HIV-1 p6 (12, 14, 19) .
In the present study, we have further mapped the domains within HIV-2 Vpx and p6 required for Vpx incorporation. In addition, we have demonstrated an interaction between Vpx and p6 in vitro, supporting the hypothesis that a protein-protein interaction between Vpx and Gag may be responsible for the recruitment of Vpx into virus particles.
Identification of Vpx packaging determinants. To examine packaging events, we used a vaccinia virus expression system that reproduces characteristics of HIV assembly (15, 23) . For this purpose, we used constructs which consist of the vpx (pTM-X) and gag-pol (pTM-GP2) genes of HIV-2 cloned into pTM3 (8) . In order to define important domains within Vpx, six mutant constructs were also cloned into pTM3 (Fig. 1A ). These were generated by PCR of HIV-2 ROD Vpx with a 5Ј primer containing an NcoI site and a 3Ј primer containing a SacI site. For the pTM-XAH construct, a 5Ј primer containing a StuI site and a 3Ј primer containing a SacI site were used to amplify residues 40 to 112. This PCR product was then ligated to pTM-X digested with StuI and SacI, which removes Vpx residues 20 to 112. For pTM-X C3S , site-directed mutagenesis was used to change the cysteine codons at positions 73, 87, and 89 to serine codons (13) . These plasmids were designed to express Vpx proteins with deletions of the amphipathic helix (pTM-XAH), the cysteine-rich domain (pTM-XCH and pTM-X73), or the proline-rich carboxyl terminus (pTM-X101, pTM-X89, and pTM-X73). Plasmids pTM-X89, pTM-X73, and pTM-XCH also have a deletion of the intervening region between the cysteine-rich region and the proline-rich terminus. Plasmid pTM-X C3S is a mutant which tests the potential role of disulfide bonds in Vpx particle incorporation. Each of the clones was confirmed by sequence analysis (20) .
The pTM3 vector contains a T7 polymerase promoter. BSC40 cells which were 90% confluent on 100-mm-diameter tissue culture plates were maintained in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal calf serum, 1 mM pyruvate, 100 U of penicillin per ml, and 100 g of streptomycin per ml. Cells were infected for 1 h at 37°C with a recombinant vaccinia virus expressing T7 polymerase (vTF7-3) at a multiplicity of infection of 10. They were then transfected with 10 g of each pTM3 construct in the presence of 10 l of Lipofectin (GIBCO). Four hours after transfection, the cells were labeled with cysteine and methionine-free Dulbecco's modified Eagle's medium containing 50 Ci of Tran 35 S-label per ml. After 20 h, the conditioned medium was clarified by centrifugation at 1,000 rpm for 5 min and lysed by the addition of 10ϫ lysis buffer (100 mM Tris-HCl [pH 7.5], 1.5 M NaCl, 10% Triton X-100, 10 mM EDTA). The cells were washed with phosphate-buffered saline, scraped off the plates, pelleted by centrifugation, and then lysed by the addition of 1ϫ lysis buffer. Nuclei were removed by centrifugation at 2,000 rpm for 10 min. Cell lysates were analyzed by immunoprecipitation with polyclonal Vpx antibody diluted 1:500 (8) to determine the levels of Vpx expression (Fig. 1B) . The antibody was able to detect each of the mutants, and no dimeric or oligomeric forms of Vpx were observed in these immunoprecipitations (data not shown). Vpx and Gag in virus-like particles were then detected by immunoprecipitation of the conditioned medium with pooled polyclonal Vpx and Gag antisera (Fig.  1C) . The 35 S-labeled proteins were analyzed by electrophoresis on a sodium dodecyl sulfate (SDS)-15% polyacrylamide gel, followed by autoradiography. The ratio of Vpx to capsid (CA) molecules was determined by scanning densitometric analysis of the two bands, followed by a correction for the relative amounts of cysteine and methionine.
The amount of Vpx observed in the lysates varied among the mutants, similar to what has been observed by others (18) . Greater than wild-type protein levels of pTM-X73, pTM-X89, and pTM-XCH are shown in the present study ( that the deletion of cysteine and methionine residues in some of the mutants is not responsible for the differences in the levels of detection of different Vpx proteins. Comparison of the amount of Vpx in cell lysates to the amount in virus-like particles indicated a reduction in the packaging ability of mutants pTM-X73 and pTM-XCH (Fig. 1C, lanes 3 and 8) . The Vpx/Gag ratio in these mutants is 0 compared to 1.5 for wildtype Vpx. In contrast, pTM-X89 is packaged nearly as efficiently as wild-type Vpx (lane 4), with a Vpx/Gag ratio of 1.1, suggesting that Vpx residues 73 to 89 are critical for incorporation into virus-like particles. Even though this region contains the conserved cysteine residues previously mentioned, these residues do not appear to be important for packaging, since the pTM-X C3S protein was also packaged into virus-like particles with wild-type efficiency (lane 7; Vpx/Gag ratio of 1.2). Additionally, neither the C-terminal stretch of prolines nor the amphipathic helix appeared to function in packaging, as both pTM-X101 and pTM-XAH are incorporated into the virus-like particles with Vpx/Gag ratios of 1.2 and 1.3, respectively (lanes 5 and 6). When the conditioned medium from cells transfected with pTM-GP2 and either pTM-X, pTM-X73, or pTM-X89 was centrifuged through a 20 to 60% equilibrium density sucrose gradient and analyzed directly by SDS-polyacrylamide gel electrophoresis (PAGE) without immunoprecipitation, only wild-type Vpx and X89 were found at the peak of the gradient (fractions 6 to 8; sucrose density, 1.14 to 1.18 g/ml) along with CA (Fig. 2) . In contrast, little or no X73 was found with CA in the peak gradient fractions when coexpressed with pTM-GP2. These findings suggest that the results from the immunoprecipitations accurately represent the constituents of virus-like particles.
Identification of p6 packaging determinants. It has previously been shown with the vaccinia virus system (8) that HIV-1 Gag is not capable of incorporating Vpx into virus-like particles. Therefore, to study functional domains within HIV-2 p6, we utilized a truncated HIV-1 Gag missing the entire p6 sequence and attached to this polyprotein various portions of HIV-2 p6 in order to generate chimeras and determine if they were able to restore the packaging ability of Vpx (Fig. 3A) . These chimeras included almost the entire HIV-2 Gag sequence shown to be sufficient for Vpx incorporation into particles (p6 2-49 ) (25) or portions of this sequence (p6 2-30 and p6 [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] ). Subscripts indicate HIV-2 p6 residues present in each chimeric Gag protein. Additional plasmids were constructed to examine the possibility that a determinant common to p6 and p6 33-49 could be involved in Vpx incorporation into viruslike particles. These included p6 2-40 , p6 , and p6 . The HIV-1 pTM(p6 Ϫ ) construct has been described previously (14) . This construct has a unique XhoI site four residues downstream from the p1 spacer peptide. This site was used for the insertion of the six different HIV-2 p6 PCR products. In addition, as a positive control, we used a construct, pTM-p6(2), which we had previously shown was able to package Vpx. This construct consists of a BglII/EcoRI fragment from HIV-2 Gag ligated into BglII/EcoRI-digested HIV-1 Gag in the pTM1 backbone. This construct has eight residues of the HIV-2 p1 spacer plus all of p6 connected in frame to a p6 Ϫ HIV-1 Gag. All of the constructs were sequenced to verify that they were correct.
Cotransfection of these constructs and pTM-X into BSC40 cells, as described for Fig. 1 , resulted in similar levels of both Vpx and Gag in the cell lysates (Fig. 3B) . When Vpx was coexpressed with pTM(p6 Ϫ ), no export of Vpx into the conditioned medium could be detected (Fig. 3C, lane 1) . Coexpression of pTM-p6(2) with Vpx allowed for the packaging of Vpx into virus-like particles (lane 2; Vpx/Gag ratio of 1.7), as did p6 2-49 (lane 5; Vpx/Gag ratio of 1.7). This latter result rules out possible involvement of the p1 peptide in Vpx packaging.
Coexpression of Vpx and p6 33-49 did not result in virion incorporation (lane 4; Vpx/Gag ratio, Ͻ0.1), and p6 2-30 packaged only a small amount of Vpx (lane 3; Vpx/Gag ratio, 0.4), suggesting that a critical domain had been disrupted in these constructs. In support of this finding, p6 2-40 , p6 , and p6 were all able to package Vpx in amounts comparable to both p6(2) and p6 2-49 (lanes 6, 7, and 8; Vpx/Gag ratios of 1.5, 1.5, and 1.7, respectively). This result suggests that the region within HIV-2 p6 required for Vpx packaging is contained between residues 15 and 40. There is a conserved region stretching from amino acids 23 to 52 in p6 of HIV-2 and SIVs but not in HIV-1 p6 (Fig. 3A, bottom) (17) . Since these are the viruses which contain Vpx, this region is an attractive candidate for the Vpx packaging signal. Our data implicate the N-terminal 17 residues of this unique region, amino acids 23 to 40 of p6, although they cannot rule out an additional contribution provided by surrounding sequences.
In vitro binding of Vpx to p6 sequences. We wanted to determine if residues 2 to 49 of HIV-2 p6 are necessary and sufficient for binding to Vpx in vitro. To do this, we utilized a glutathione S-transferase (GST) fusion protein binding assay. We had previously demonstrated that a GST fusion protein containing the complete HIV-2 Pr55 gag precursor is able to bind Vpx, whereas a GST fusion protein with only HIV-2 p6 is unable to bind Vpx (data not shown). Since we were unable to determine whether the p6 portion of the latter fusion protein was stable or whether it had adopted its wild-type conformation, we used HIV-1 Gag and HIV-1/HIV-2 chimeric fusion proteins in the following assays. pTM-p6 2-49 and pTM(p6 Ϫ ) were digested with NcoI and StuI, and the NcoI site was filled in with Klenow. The constructs were then cloned into the SmaI site of pGEX-2T and expressed as fusion proteins with GST to allow easy purification of the fusion proteins on glutathioneSepharose beads (22) .
As a source of binding material, cell lysate from a 100-mmdiameter dish of BSC40 cells transfected with pTM-X was harvested as previously described. This lysate was precleared with 40 l of glutathione beads and then added to either GST alone, GST-p6 Ϫ , or GST-p6 . The samples were rotated overnight at 4°C in the presence of 40 l of glutathione beads and then washed three times with 1ϫ lysis buffer. Proteins were eluted off the beads by the addition of 2ϫ sample buffer and heated to 95°C for 5 min. They were then electrophoresed on an SDS-12% polyacrylamide gel, and the binding of Vpx was assayed by Western blotting with ␣Vpx antiserum followed by a peroxidase-conjugated donkey anti-rabbit antibody. Bound secondary antibody was detected by treating the filter with Amersham enhanced chemiluminescent reagents. Using this approach, we were able to detect binding of Vpx to chimeric HIV-1/HIV-2 Gag sequences (Fig. 4) . Vpx interacts with GSTp6 2-49 (lane 7), whereas it does not bind to GST alone (lane 3). There is a low level of Vpx binding to the GST-p6 Ϫ construct (lane 5), but it is significantly less than that binding to GSTp6 , even though equivalent levels of fusion proteins were used in these assays as determined by Coomassie staining (data not shown).
Residues 73 to 89 of Vpx are required for in vitro binding to Gag. Since residues 73 to 89 of HIV-2 Vpx appear to be important for incorporation into virus-like particles, we wanted to determine if they were necessary for in vitro interaction between Vpx and Gag. Coupled in vitro transcription and translation of Vpx73 and Vpx89 truncation proteins were performed with pTM-X73 and pTM-X89 as templates in the Promega T7 TnT system. Translations were done in the presence of Tran 35 S-label at a final concentration of 0.4 mCi/ml. These labeled proteins were then used in a binding assay with a GST-Gag fusion protein. This protein was generated from a clone made by digesting pTM-GP2 with NcoI and EcoRI, followed by Klenow-mediated fill-in of both sites and ligation of the cDNA into the SmaI site of pGEX-2T. Bound proteins were detected by electrophoresis on an SDS-15% PAGE gel, followed by autoradiography. With similar levels of Vpx73 and Vpx89, significant levels of binding to GST-Gag are observed only with Vpx89 (Fig. 5 ). In combination with the previous data obtained by the vaccinia virus expression system, the results from this binding assay suggest that residues 73 to 89 of HIV-2 Vpx are involved in a protein-protein interaction with HIV-2 Gag, which then allows for incorporation into virus-like particles.
Our results define specific Vpx packaging components in both HIV-2 Vpx and p6. This region defined within Vpx is similar to what has been defined in SIV Vpx; however, involvement of the cysteine residues in packaging events has been excluded. The p6 region required for Vpx packaging has been more narrowly defined to residues 15 to 40, which contains a unique region not found in HIV-1. The p6 region identified here as being important for Vpx virion incorporation differs from that found for HIV-1 Vpr incorporation (14) . The latter has been demonstrated to require residues 35 to 47 of HIV-1 p6, and specifically, a (leucine-X-X) 4 motif (where X is any amino acid) appears to be important for packaging. No such motif exists within residues 15 to 40 of HIV-2 p6, suggesting that these two accessory proteins utilize different components within p6 for their incorporation into the virion. This possibility is supported by the finding of KewalRamani and Emerman that HIV-2 Vpx does not compete with Vpr for particle incorporation in vivo (11) .
Residues within both HIV-2 p6 and Vpx demonstrated to be important for Vpx packaging by the vaccinia virus system were also shown to enhance Vpx binding in a GST capture assay. This result suggests that after translation, Vpx binds to Pr55 gag in a manner that requires residues 15 to 40 of p6 and 73 to 89 of Vpx. Additional studies will be required to address more specifically the characteristics of these sequences which are required for protein-protein interactions and virion incorporation.
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